Dostarlimab – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 28 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Dostarlimab - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Dostarlimab is an anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers.  Dostarlimab is a monoclonal antibody used as a medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody. Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Dostarlimab is an anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers.  Dostarlimab is a monoclonal antibody used as a medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody. Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1).[rx] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some...

Key Takeaways

  • This article explains Mechanism of action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Dostarlimab is an anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers.  Dostarlimab is a monoclonal antibody used as a medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody. Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1).[rx] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses – some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically attempt to destroy the cancerous cells.[rx] Agents acting on the PD-1 pathway, such as nivolumab and pembrolizumab, facilitate endogenous immune-mediated anti-tumor activity and may therefore be used to treat a wide variety of cancers, including those of the skin, lung, kidneys, and liver.

In April 2021, dostarlimab was granted accelerated approval by the FDA – as GlaxoSmithKline’s dostarlimab-gxly (Jemperli) – for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR) endometrial cancer experiencing disease progression despite treatment with platinum-containing chemotherapy regimens.[rx] As this accelerated approval was granted only for the treatment of dMMR endometrial cancers, it was approved alongside a companion diagnostic device – the VENTANA MMR RxDx Panel – for use in selecting appropriate patients for treatment.[rx]

Dostarlimab is currently under investigation for the treatment of rectal cancers with mismatch repair deficiency. A prospective phase II study in patients with mismatch repair-deficient locally advanced rectal cancer resulted in all twelve patients exhibiting a complete clinical response.[rx]

Mechanism of action

Approximately 13-30% of recurrent endometrial cancers involve microsatellite instability (MSI) or mismatch repair deficiency (dMMR).[rx,rx] The mutations resulting in dMMR endometrial cancers are primarily somatic in nature (~90%), although 5-10% of cases involve germline mutations.[rx] Cancers that have mutations resulting in dMMR can upregulate the expression of programmed death receptor-1 (PD-1) ligands 1 and 2 (PD-L1 and -L2) – PD-1 is found on T-cells and, when activated, inhibits their proliferation and the production of cytokines.[rx] The binding of these ligands to PD-1 thereby functions as an immune checkpoint that downregulates the anti-tumor immune response.[rx]

Dostarlimab is a monoclonal antibody targeted against PD-1 – it binds to the receptor and prevents interactions with PD-L1 and PD-L2, thus allowing the anti-tumor immune response to proceed unimpeded.[rx]

Dostarlimab is an immunotherapy that facilitates the body’s endogenous anti-tumor immune response in the treatment of cancer.[rx] It is administered over a span of 30 minutes via intravenous infusion every three to six weeks depending on the cycle.[rx]

Agents that interfere with the PD-1/PD-L1 pathway, including dostarlimab, remove an important immune system inhibitory response and may therefore induce immune-mediated adverse reactions which can be severe or fatal. These reactions can occur in any organ system and can occur at any time after starting therapy, and while they most often manifest during therapy they may also appear after discontinuing the causative agent. Patients receiving therapy with dostarlimab should be monitored closely for evidence of an underlying immune-mediated reaction and evaluated and treated promptly if an immune-mediated reaction is suspected.[rx]

Indications

  • Dostarlimab-gxly is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed despite ongoing or prior treatment with a platinum-containing chemotherapy regimen.
  • In the United States, dostarlimab is indicated for the treatment of adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen. Platinum-based agents such as cisplatin, carboplatin, and oxaliplatin are the mainstays of treatment when it comes to cancer chemotherapy treatment.[rx] It is also indicated for the treatment of solid tumors.[rx]
  • In the European Union, dostarlimab is indicated as monotherapy for the treatment of adults with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.
  • For the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
  • Advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer
  • Recurrent Mismatch Repair-deficient (dMMR) Endometrial Cancer

Use in Cancer

Dostarlimab-gxly is approved to treat adults with mismatch repair deficient (dMMR) cancer that has come back or is advanced, including:

Dostarlimab-gxly is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.

Dostarlimab-gxly is also being studied in the treatment of other types of cancer.

Contraindications

  • overactive thyroid gland
  • a condition with low thyroid hormone levels
  • type 1 insulin is low or not working well. সহজ বাংলা: রক্তে চিনি বেশি থাকার রোগ।" data-rx-term="diabetes" data-rx-definition="Diabetes is a condition where blood sugar stays too high because insulin is low or not working well. সহজ বাংলা: রক্তে চিনি বেশি থাকার রোগ।">diabetes mellitus
  • severely decreased function of cortex of adrenal gland
  • a type of infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation of the lung called interstitial pneumonitis
  • infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation of the large intestine
  • infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation of the liver called hepatitis
  • kidney infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation
  • high blood sugar
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation of the pituitary gland

Dosage

Strengths: gxly 500 mg/10 mL

Endometrial Carcinoma

Initial dose:

  • Dose 1 through Dose 4: 500 mg IV over 30 minutes every 3 weeks

Maintenance dose:

  • Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1000 mg IV over 30 minutes every 6 weeks

Duration of therapy:

  • Until disease progression or unacceptable toxicity

Dose Adjustments

  • No dose reductions of this drug are recommended. In general, withhold therapy for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue therapy for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce corticosteroid dose to 10 mg or less prednisone equivalent per day within 12 weeks of initiating steroids.

DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
PNEUMONITIS:

  • Grade 2: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids
  • Grade 3 or 4 or recurrent Grade 2: Permanently discontinue therapy.

COLITIS:

  • Grade 2 or 3: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids
  • Grade 4: Permanently discontinue therapy.

HEPATITIS WITH NO TUMOR INVOLVEMENT OF THE LIVER:

  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) increases to more than 3 and up to 8 times upper limit of normal (ULN) or total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin (TB) increases to more than 1.5 and up to 3 x ULN: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroid. AST or ALT increases to more than 8 x ULN or TB increases to more than 3 x ULN: Permanently discontinue therapy.

HEPATITIS WITH TUMOR INVOLVEMENT OF THE LIVER (if AST and ALT are less than or equal to ULN at baseline in patients with liver involvement, withhold or permanently discontinue this drug based on recommendations for hepatitis with no liver involvement):

  • Baseline AST or ALT is more than 1 and up to 3 x ULN and increases to more than 5 and up to 10 x ULN or baseline AST or ALT is more than 3 and up to 5 x ULN and increases to more than 8 and up to 10 x ULN OR baseline AST or ALT is more than 3 and up to 5 x ULN and increases to more than 8 and up to 10 x ULN: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids
  • AST or ALT increases to more than 10 x ULN or TB increases to more than 3 x ULN: Permanently discontinue therapy.

ENDOCRINOPATHIES:

  • Grade 2, 3, or 4: Withhold therapy if not clinically stable; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids

NEPHRITIS WITH RENAL DYSFUNCTION:

  • Grade 2 or 3 increased creatinine: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids
  • Grade 4 increased creatinine: Permanently discontinue therapy.

EXFOLIATIVE DERMATOLOGIC CONDITIONS:

  • Suspected Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS): Withhold therapy if not clinically stable; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids
  • Confirmed SJS, TEN, or DRESS: Permanently discontinue therapy.

MYOCARDITIS:

  • Grade 2, 3, or 4: Permanently discontinue therapy.

NEUROLOGICAL TOXICITIES:

  • Grade 2: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids
  • Grade 3 or 4: Permanently discontinue therapy.

INFUSION-RELATED REACTIONS:

  • Grade 1 or 2: Interrupt or slow the rate of infusion.
  • Grade 3 or 4: Permanently discontinue therapy.

Administration advice:

  • Administer infusion solution IV over 30 minutes through an IV line using tubing made of polyvinyl chloride or platinum-cured silicon; fittings made of polyvinyl chloride or polycarbonate; and a sterile, non-pyrogenic, low-protein binding, 0.2-micron, in-line, or add-on filter.
  • Do not administer this drug as an IV push or bolus injection.
  • Do not co-administer other drugs through the same infusion line.

Side Effects

The Most Common

  • nausea
  • constipation
  • fatigue
  • muscle or joint pain
  • cough, chest pain, or shortness of breath
  • diarrhea; increase in the number of bowel movements; black, tarry, sticky stools, or stools that have blood or mucus in them; or stomach-area pain or tenderness
  • yellowing of skin or eyes, dark-colored urine, bleeding or bruising more easily than normal, loss of appetite, severe nausea or vomiting, decreased energy, or pain on the right side of the stomach area
  • headaches, including those that are unusual or will not go away
  • changes in mood or behavior (decreased sex drive, irritability, or forgetfulness)
  • deepening of voice or hoarseness
  • changes in weight (gain or loss)
  • weakness
  • hair loss
  • dizziness or fainting
  • vision changes
  • increased sweating
  • increased urination
  • increased sensitivity to light
  • fast heartbeat
  • feeling more hungry or thirsty than usual
  • feeling cold
  • change in amount or color of urine; ankle swelling; blood in urine; or loss of appetite
  • pale skin or shortness of breath
  • rash; skin blisters, peeling, or sores; itching; painful sores or ulcers in mouth, nose, throat, or genital area; fever or flu-like symptoms; or swollen lymph nodes
  • rash, stomach area pain, or diarrhea
  • swollen lymph nodes, rash or tender skin lumps, cough, shortness of breath, vision changes, or eye pain
  • confusion, fever, muscle weakness, balance problems, nausea, vomiting, stiff neck, memory problems, or seizures
  • hallucinations (seeing things or hearing voices that do not exist)

More common

  • Bladder pain
  • bloody or cloudy urine
  • constipation
  • depression
  • difficult, burning, or painful urination
  • dry skin and hair
  • feeling cold
  • frequent urge to urinate
  • hair loss
  • hoarseness or husky voice
  • loss of appetite
  • lower back or side pain
  • muscle cramps and stiffness
  • pale skin
  • slow heartbeat
  • sore tongue
  • trouble breathing
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • weight gain
  • Agitation
  • chest pain or tightness
  • chills
  • coma
  • confusion
  • cough
  • cough producing mucus
  • decreased urine output
  • diarrhea
  • dizziness
  • fever
  • general feeling of discomfort or illness
  • headache
  • hostility
  • irritability
  • lethargy
  • muscle twitching
  • nausea
  • nervousness
  • rapid weight gain
  • seizures
  • sensitivity to heat
  • stomach cramps, tenderness, or pain
  • stupor
  • sweating
  • swelling of the face, feet, lower legs, ankles, or hands
  • thickening of bronchial secretions
  • trouble sleeping
  • watery or bloody diarrhea
  • weight loss

Rare

  • Anxiety
  • back or leg pain
  • black, tarry stools
  • bleeding gums
  • bloating
  • blood in the stools
  • blue or pale skin
  • blurred vision
  • burning, tingling, numbness, or pain in the hands, arms, feet, or legs
  • burning feeling in the chest or stomach
  • change in vision
  • chest pain, possibly moving to the left arm, neck, or shoulder
  • dark urine
  • darkening of the skin
  • drowsiness
  • dry mouth
  • eye pain
  • fainting
  • fast heartbeat
  • general body swelling
  • inability to move the arms and legs
  • indigestion
  • joint pain
  • light-colored stools
  • lightheadedness
  • loss of consciousness
  • loss of strength or energy
  • muscle aches, pain, tenderness, or weakness
  • nosebleeds
  • numbness or tingling in the fingers, face, or feet
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • partial or slight paralysis
  • pinpoint red spots on the skin
  • rapid, shallow breathing
  • redness of the eye
  • sensation of pins and needles
  • sensitivity of the eye to light
  • severe headache
  • skin rash, redness, soreness, or itching
  • sores, welting, or blisters
  • stabbing pain
  • stiff neck or back
  • stomach discomfort or upset
  • sudden numbness and weakness in the arms and legs
  • swollen, painful, or tender lymph glands in the neck, armpit, or groin
  • tearing
  • upper right abdominal or stomach pain
  • vomiting
  • yellow eyes and skin

Drug Interaction

Pregnancy and Lactation

US FDA pregnancy category Not Assigned

Pregnancy

Dostarlimab can cause harm to a fetus. The death of the fetus can occur from the immune system’s reaction to the fetus through the examination of its mechanism in animal studies. Dostarlimab is a human immunoglobulin G (IgG4), which could permeate through the placental barrier. This may risk harm to the developing fetus as the drug may be passed on from the mother. Data is not available regarding the presence of dostarlimab in breast milk.[rx]

Lactation

Use should be avoided. Excreted into human milk: Unknown. Excreted into animal milk: Data not available
Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during therapy and for at least 4 months after the last dose.

How should this medicine be used?

Dostarlimab-gxly injection comes as a solution (liquid) to inject intravenously (into a vein) over 30 minutes by a doctor or nurse in a medical facility or infusion center. It is usually given once every 3 weeks for 4 cycles, and then once every 6 weeks for as long as your doctor recommends you receive treatment.

Dostarlimab-gxly injection may cause serious or life-threatening reactions during an infusion. A doctor or nurse will watch you closely while you are receiving the infusion to be sure you are not having a serious reaction to the medication. Tell your doctor or nurse immediately if you experience any of the following symptoms that may occur during the infusion: chills, flushing, shaking, dizziness, shortness of breath, wheezing, fever, itching, rash, back or neck pain, or feeling faint.

Your doctor may slow down your infusion, permanently or temporarily stop your dostarlimab-gxly injection treatment, or treat you with additional medications depending on your response to the medication and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment.

Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with dostarlimab-gxly injection each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide.

What special precautions should I follow?

Before receiving dostarlimab-gxly injection,

  • tell your doctor and pharmacist if you are allergic to dostarlimab-gxly, any other medications, or any of the ingredients in dostarlimab-gxly injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you have ever had an organ or bone marrow transplant and if you have or have ever had radiation therapy to your chest area; an autoimmune disease such as Crohn’s disease (a condition in which the immune system attacks the lining of the digestive tract causing pain, diarrhea, weight loss, and fever), ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum), or lupus (condition in which the immune system attacks many tissues and organs including the skin, joints, blood, and kidneys); any condition that affects your nervous system such as myasthenia gravis (a disorder of the nervous system that causes muscle weakness) or Guillain-Barré syndrome (weakness, tingling, and possible paralysis due to sudden nerve damage); any type of lung disease or breathing problems; thyroid problems; or liver disease.
  • tell your doctor if you are pregnant or plan to become pregnant. You will need to take a pregnancy test before you receive dostarlimab-gxly. You should not become pregnant while you are receiving a dostarlimab-gxly injection and for at least 4 months after your final dose. If you become pregnant while receiving a dostarlimab-gxly injection, call your doctor immediately. Dostarlimab-gxly injection may harm the fetus.
  • tell your doctor if you are breastfeeding or plan to breastfeed. You should not breastfeed while receiving a dostarlimab-gxly injection and for 4 months after your final dose.

References

RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Dostarlimab – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of action Approximately 13-30% of recurrent endometrial cancers involve microsatellite instability (MSI) or mismatch repair deficiency (dMMR).[rx,rx] The mutations resulting in dMMR endometrial cancers are primarily somatic in nature (~90%), although 5-10% of cases involve germline mutations.[rx] Cancers that have mutations resulting in dMMR can upregulate the expression of programmed death receptor-1 (PD-1) ligands 1 and 2 (PD-L1 and -L2) - PD-1 is found on T-cells and, when activated, inhibits their proliferation and the production of cytokines.[rx] The binding of these ligands to PD-1 thereby functions as an immune checkpoint that downregulates the anti-tumor immune response.[rx] Dostarlimab is a monoclonal antibody targeted against PD-1 - it binds to the receptor and prevents interactions with PD-L1 and PD-L2, thus allowing the anti-tumor immune response to proceed unimpeded.[rx] Dostarlimab is an immunotherapy that facilitates the body's endogenous anti-tumor immune response in the treatment of cancer.[rx] It is administered over a span of 30 minutes via intravenous infusion every three to six weeks depending on the cycle.[rx] Agents that interfere with the PD-1/PD-L1 pathway, including dostarlimab, remove an important immune system inhibitory response and may therefore induce immune-mediated adverse reactions which can be severe or fatal. These reactions can occur in any organ system and can occur at any time after starting therapy, and while they most often manifest during therapy they may also appear after discontinuing the causative agent. Patients receiving therapy with dostarlimab should be monitored closely for evidence of an underlying immune-mediated reaction and evaluated and treated promptly if an immune-mediated reaction is suspected.[rx] Indications Dostarlimab-gxly is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed despite ongoing or prior treatment with a platinum-containing chemotherapy regimen. In the United States, dostarlimab is indicated for the treatment of adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen. Platinum-based agents such as cisplatin, carboplatin, and oxaliplatin are the mainstays of treatment when it comes to cancer chemotherapy treatment.[rx] It is also indicated for the treatment of solid tumors.[rx] In the European Union, dostarlimab is indicated as monotherapy for the treatment of adults with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen. For the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an approved test, that has progressed on or following prior treatment with a platinum-containing regimen. Advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer Recurrent Mismatch Repair-deficient (dMMR) Endometrial Cancer Use in Cancer Dostarlimab-gxly is approved to treat adults with mismatch repair deficient (dMMR) cancer that has come back or is advanced, including: Endometrial cancer was treated with platinum chemotherapy, but it did not work or is no longer working. Solid tumors that got worse during or after other treatments and cannot be treated with other therapies. Dostarlimab-gxly is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients. Dostarlimab-gxly is also being studied in the treatment of other types of cancer. Contraindications overactive thyroid gland a condition with low thyroid hormone levels type 1 diabetes mellitus severely decreased function of cortex of adrenal gland a type of inflammation of the lung called interstitial pneumonitis inflammation of the large intestine inflammation of the liver called hepatitis kidney inflammation high blood sugar pregnancy a patient who is producing milk and breastfeeding inflammation of the pituitary gland Dosage Strengths: gxly 500 mg/10 mL Endometrial Carcinoma Initial dose: Dose 1 through Dose 4: 500 mg IV over 30 minutes every 3 weeks Maintenance dose: Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1000 mg IV over 30 minutes every 6 weeks Duration of therapy: Until disease progression or unacceptable toxicity Dose Adjustments No dose reductions of this drug are recommended. In general, withhold therapy for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue therapy for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce corticosteroid dose to 10 mg or less prednisone equivalent per day within 12 weeks of initiating steroids. DOSE MODIFICATIONS FOR ADVERSE REACTIONS: PNEUMONITIS: Grade 2: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids Grade 3 or 4 or recurrent Grade 2: Permanently discontinue therapy. COLITIS: Grade 2 or 3: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids Grade 4: Permanently discontinue therapy. HEPATITIS WITH NO TUMOR INVOLVEMENT OF THE LIVER: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) increases to more than 3 and up to 8 times upper limit of normal (ULN) or total bilirubin (TB) increases to more than 1.5 and up to 3 x ULN: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroid. AST or ALT increases to more than 8 x ULN or TB increases to more than 3 x ULN: Permanently discontinue therapy. HEPATITIS WITH TUMOR INVOLVEMENT OF THE LIVER (if AST and ALT are less than or equal to ULN at baseline in patients with liver involvement, withhold or permanently discontinue this drug based on recommendations for hepatitis with no liver involvement): Baseline AST or ALT is more than 1 and up to 3 x ULN and increases to more than 5 and up to 10 x ULN or baseline AST or ALT is more than 3 and up to 5 x ULN and increases to more than 8 and up to 10 x ULN OR baseline AST or ALT is more than 3 and up to 5 x ULN and increases to more than 8 and up to 10 x ULN: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids AST or ALT increases to more than 10 x ULN or TB increases to more than 3 x ULN: Permanently discontinue therapy. ENDOCRINOPATHIES: Grade 2, 3, or 4: Withhold therapy if not clinically stable; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids NEPHRITIS WITH RENAL DYSFUNCTION: Grade 2 or 3 increased creatinine: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids Grade 4 increased creatinine: Permanently discontinue therapy. EXFOLIATIVE DERMATOLOGIC CONDITIONS: Suspected Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS): Withhold therapy if not clinically stable; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids Confirmed SJS, TEN, or DRESS: Permanently discontinue therapy. MYOCARDITIS: Grade 2, 3, or 4: Permanently discontinue therapy. NEUROLOGICAL TOXICITIES: Grade 2: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper; permanently discontinue therapy if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids Grade 3 or 4: Permanently discontinue therapy. INFUSION-RELATED REACTIONS: Grade 1 or 2: Interrupt or slow the rate of infusion. Grade 3 or 4: Permanently discontinue therapy. Administration advice: Administer infusion solution IV over 30 minutes through an IV line using tubing made of polyvinyl chloride or platinum-cured silicon; fittings made of polyvinyl chloride or polycarbonate; and a sterile, non-pyrogenic, low-protein binding, 0.2-micron, in-line, or add-on filter. Do not administer this drug as an IV push or bolus injection. Do not co-administer other drugs through the same infusion line. Side Effects The Most Common nausea constipation fatigue muscle or joint pain cough, chest pain, or shortness of breath diarrhea; increase in the number of bowel movements; black, tarry, sticky stools, or stools that have blood or mucus in them; or stomach-area pain or tenderness yellowing of skin or eyes, dark-colored urine, bleeding or bruising more easily than normal, loss of appetite, severe nausea or vomiting, decreased energy, or pain on the right side of the stomach area headaches, including those that are unusual or will not go away changes in mood or behavior (decreased sex drive, irritability, or forgetfulness) deepening of voice or hoarseness changes in weight (gain or loss) weakness hair loss dizziness or fainting vision changes increased sweating increased urination increased sensitivity to light fast heartbeat feeling more hungry or thirsty than usual feeling cold change in amount or color of urine; ankle swelling; blood in urine; or loss of appetite pale skin or shortness of breath rash; skin blisters, peeling, or sores; itching; painful sores or ulcers in mouth, nose, throat, or genital area; fever or flu-like symptoms; or swollen lymph nodes rash, stomach area pain, or diarrhea swollen lymph nodes, rash or tender skin lumps, cough, shortness of breath, vision changes, or eye pain confusion, fever, muscle weakness, balance problems, nausea, vomiting, stiff neck, memory problems, or seizures hallucinations (seeing things or hearing voices that do not exist) More common Bladder pain bloody or cloudy urine constipation depression difficult, burning, or painful urination dry skin and hair feeling cold frequent urge to urinate hair loss hoarseness or husky voice loss of appetite lower back or side pain muscle cramps and stiffness pale skin slow heartbeat sore tongue trouble breathing unusual bleeding or bruising unusual tiredness or weakness weight gain Agitation chest pain or tightness chills coma confusion cough cough producing mucus decreased urine output diarrhea dizziness fever general feeling of discomfort or illness headache hostility irritability lethargy muscle twitching nausea nervousness rapid weight gain seizures sensitivity to heat stomach cramps, tenderness, or pain stupor sweating swelling of the face, feet, lower legs, ankles, or hands thickening of bronchial secretions trouble sleeping watery or bloody diarrhea weight loss Rare Anxiety back or leg pain black, tarry stools bleeding gums bloating blood in the stools blue or pale skin blurred vision burning, tingling, numbness, or pain in the hands, arms, feet, or legs burning feeling in the chest or stomach change in vision chest pain, possibly moving to the left arm, neck, or shoulder dark urine darkening of the skin drowsiness dry mouth eye pain fainting fast heartbeat general body swelling inability to move the arms and legs indigestion joint pain light-colored stools lightheadedness loss of consciousness loss of strength or energy muscle aches, pain, tenderness, or weakness nosebleeds numbness or tingling in the fingers, face, or feet pains in the stomach, side, or abdomen, possibly radiating to the back partial or slight paralysis pinpoint red spots on the skin rapid, shallow breathing redness of the eye sensation of pins and needles sensitivity of the eye to light severe headache skin rash, redness, soreness, or itching sores, welting, or blisters stabbing pain stiff neck or back stomach discomfort or upset sudden numbness and weakness in the arms and legs swollen, painful, or tender lymph glands in the neck, armpit, or groin tearing upper right abdominal or stomach pain vomiting yellow eyes and skin Drug Interaction DRUG INTERACTION Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Dostarlimab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Dostarlimab. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Dostarlimab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dostarlimab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Dostarlimab. Amivantamab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Anifrolumab is combined with Dostarlimab. Ansuvimab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Ansuvimab. Anthrax The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Dostarlimab. Antilymphocyte The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Dostarlimab. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dostarlimab. Articaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Articaine. Asfotase alfa The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Dostarlimab. Atezolizumab The risk or severity of adverse effects can be increased when Atezolizumab is combined with Dostarlimab. Atoltivimab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Atoltivimab. Avelumab The risk or severity of adverse effects can be increased when Avelumab is combined with Dostarlimab. Bamlanivimab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Bamlanivimab. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Dostarlimab. Bebtelovimab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Bebtelovimab. Belantamab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Belantamab mafodotin. Belimumab The risk or severity of adverse effects can be increased when Belimumab is combined with Dostarlimab. Benralizumab The risk or severity of adverse effects can be increased when Benralizumab is combined with Dostarlimab. Benzocaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Benzyl alcohol. Besilesomab The risk or severity of adverse effects can be increased when Besilesomab is combined with Dostarlimab. Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dostarlimab. Bezlotoxumab The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Dostarlimab. Bimekizumab The risk or severity of adverse effects can be increased when Bimekizumab is combined with Dostarlimab. Blinatumomab The risk or severity of adverse effects can be increased when Blinatumomab is combined with Dostarlimab. Brentuximab vedotin The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dostarlimab. Brodalumab The risk or severity of adverse effects can be increased when Brodalumab is combined with Dostarlimab. Brolucizumab The risk or severity of adverse effects can be increased when Brolucizumab is combined with Dostarlimab. Bupivacaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Bupivacaine. Burosumab The risk or severity of adverse effects can be increased when Burosumab is combined with Dostarlimab. Butacaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Butamben. Canakinumab The risk or severity of adverse effects can be increased when Canakinumab is combined with Dostarlimab. Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dostarlimab. Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dostarlimab. Capsaicin The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Capsaicin. Casirivimab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Casirivimab. Catumaxomab The risk or severity of adverse effects can be increased when Catumaxomab is combined with Dostarlimab. Cemiplimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Dostarlimab. Certolizumab pegol The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Dostarlimab. Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Dostarlimab. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Chloroprocaine. Cilgavimab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Cilgavimab. Cinchocaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Cinchocaine. Cocaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Cocaine. Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Dostarlimab. Daratumumab The risk or severity of adverse effects can be increased when Daratumumab is combined with Dostarlimab. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dostarlimab. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Dostarlimab. Dienestrol Dienestrol may increase the thrombogenic activities of Dostarlimab. Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Dostarlimab. Digoxin Immune The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dostarlimab. Dinutuximab The risk or severity of adverse effects can be increased when Dinutuximab is combined with Dostarlimab. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Diphenhydramine. Dulaglutide The risk or severity of adverse effects can be increased when Dulaglutide is combined with Dostarlimab. Dupilumab The risk or severity of adverse effects can be increased when Dupilumab is combined with Dostarlimab. Durvalumab The risk or severity of adverse effects can be increased when Durvalumab is combined with Dostarlimab. Dyclonine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Dyclonine. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Dostarlimab. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Dostarlimab. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Dostarlimab. Eflapegrastim The risk or severity of adverse effects can be increased when Eflapegrastim is combined with Dostarlimab. Eftrenonacog alfa The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Dostarlimab. Elotuzumab The risk or severity of adverse effects can be increased when Elotuzumab is combined with Dostarlimab. Emapalumab The risk or severity of adverse effects can be increased when Emapalumab is combined with Dostarlimab. Emicizumab The risk or severity of adverse effects can be increased when Emicizumab is combined with Dostarlimab. Eptinezumab The risk or severity of adverse effects can be increased when Eptinezumab is combined with Dostarlimab. Erenumab The risk or severity of adverse effects can be increased when Erenumab is combined with Dostarlimab. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dostarlimab. Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Dostarlimab. Estetrol Estetrol may increase the thrombogenic activities of Dostarlimab. Estradiol Estradiol may increase the thrombogenic activities of Dostarlimab. Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Dostarlimab. Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Dostarlimab. Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Dostarlimab. Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Dostarlimab. Estriol Estriol may increase the thrombogenic activities of Dostarlimab. Estrone Estrone may increase the thrombogenic activities of Dostarlimab. Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Dostarlimab. Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Dostarlimab. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Etidocaine. Evolocumab The risk or severity of adverse effects can be increased when Evolocumab is combined with Dostarlimab. Fanolesomab The risk or severity of adverse effects can be increased when Fanolesomab is combined with Dostarlimab. Fremanezumab The risk or severity of adverse effects can be increased when Fremanezumab is combined with Dostarlimab. Galcanezumab The risk or severity of adverse effects can be increased when Galcanezumab is combined with Dostarlimab. Gemtuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dostarlimab. Golimumab The risk or severity of adverse effects can be increased when Golimumab is combined with Dostarlimab. Guselkumab The risk or severity of adverse effects can be increased when Guselkumab is combined with Dostarlimab. Hepatitis globulin The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Dostarlimab. Human globulin The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Dostarlimab. immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dostarlimab. Rho(D) immune globulin The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Dostarlimab. Human  globulin The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Dostarlimab. Ibalizumab The risk or severity of adverse effects can be increased when Ibalizumab is combined with Dostarlimab. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dostarlimab. Idarucizumab The risk or severity of adverse effects can be increased when Idarucizumab is combined with Dostarlimab. Imdevimab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Imdevimab. Imlifidase The therapeutic efficacy of Dostarlimab can be decreased when used in combination with Imlifidase. Inebilizumab The risk or severity of adverse effects can be increased when Inebilizumab is combined with Dostarlimab. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Dostarlimab. Inotuzumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Dostarlimab. Ipilimumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Dostarlimab. Isatuximab The risk or severity of adverse effects can be increased when Isatuximab is combined with Dostarlimab. Ixekizumab The risk or severity of adverse effects can be increased when Ixekizumab is combined with Dostarlimab. Lanadelumab The risk or severity of adverse effects can be increased when Lanadelumab is combined with Dostarlimab. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Levobupivacaine. Lidocaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Lidocaine. Loncastuximab tesirine The risk or severity of adverse effects can be increased when Dostarlimab is combined with Loncastuximab tesirine. Maftivimab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Maftivimab. Margetuximab The risk or severity of adverse effects can be increased when Margetuximab is combined with Dostarlimab. Meloxicam The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Meloxicam. Mepivacaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Dostarlimab. Mestranol Mestranol may increase the thrombogenic activities of Dostarlimab. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dostarlimab. Mirvetuximab The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Dostarlimab. Mogamulizumab The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Dostarlimab. Mosunetuzumab The risk or severity of adverse effects can be increased when Mosunetuzumab is combined with Dostarlimab. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Dostarlimab. Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Dostarlimab. Necitumumab The risk or severity of adverse effects can be increased when Necitumumab is combined with Dostarlimab. Nivolumab The risk or severity of adverse effects can be increased when Nivolumab is combined with Dostarlimab. Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Dostarlimab. Obinutuzumab The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Dostarlimab. Ocrelizumab The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Dostarlimab. Odesivimab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Odesivimab. Ofatumumab The risk or severity of adverse effects can be increased when Ofatumumab is combined with Dostarlimab. Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Dostarlimab. Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Dostarlimab. Oxetacaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Oxybuprocaine. Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Dostarlimab. Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Dostarlimab. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Dostarlimab. Pembrolizumab The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Dostarlimab. Pertuzumab The risk or severity of adverse effects can be increased when Pertuzumab is combined with Dostarlimab. Phenol The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Phenol. Polatuzumab vedotin The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Dostarlimab. Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Dostarlimab. Pramocaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Pramocaine. Prilocaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Prilocaine. Procaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Procaine. Proparacaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Propoxycaine. Quinestrol Quinestrol may increase the thrombogenic activities of Dostarlimab. Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Dostarlimab. Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Dostarlimab. Ravulizumab The risk or severity of adverse effects can be increased when Ravulizumab is combined with Dostarlimab. Raxibacumab The risk or severity of adverse effects can be increased when Raxibacumab is combined with Dostarlimab. Reslizumab The risk or severity of adverse effects can be increased when Reslizumab is combined with Dostarlimab. Risankizumab The risk or severity of adverse effects can be increased when Risankizumab is combined with Dostarlimab. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Dostarlimab. Romosozumab The risk or severity of adverse effects can be increased when Romosozumab is combined with Dostarlimab. Ropivacaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Ropivacaine. Sacituzumab The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Dostarlimab. Sarilumab The risk or severity of adverse effects can be increased when Sarilumab is combined with Dostarlimab. Secukinumab The risk or severity of adverse effects can be increased when Secukinumab is combined with Dostarlimab. Siltuximab The risk or severity of adverse effects can be increased when Siltuximab is combined with Dostarlimab. Sotrovimab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Sotrovimab. Spesolimab The risk or severity of adverse effects can be increased when Spesolimab is combined with Dostarlimab. Sulesomab The risk or severity of adverse effects can be increased when Sulesomab is combined with Dostarlimab. Sutimlimab The risk or severity of adverse effects can be increased when Sutimlimab is combined with Dostarlimab. SEstrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Dostarlimab. SEstrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Dostarlimab. Tafasitamab The risk or severity of adverse effects can be increased when Tafasitamab is combined with Dostarlimab. Teplizumab The risk or severity of adverse effects can be increased when Teplizumab is combined with Dostarlimab. Tetanus immune The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Dostarlimab. Tetracaine The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Tetracaine. Tezepelumab The risk or severity of adverse effects can be increased when Tezepelumab is combined with Dostarlimab. Tibolone Tibolone may increase the thrombogenic activities of Dostarlimab. Tildrakizumab The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Dostarlimab. Tisotumab vedotin The risk or severity of adverse effects can be increased when Dostarlimab is combined with Tisotumab vedotin. Tixagevimab The risk or severity of adverse effects can be increased when Dostarlimab is combined with Tixagevimab. Tocilizumab The risk or severity of adverse effects can be increased when Tocilizumab is combined with Dostarlimab. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Dostarlimab. Tralokinumab The risk or severity of adverse effects can be increased when Tralokinumab is combined with Dostarlimab. Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dostarlimab. Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Dostarlimab. Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Dostarlimab. Tremelimumab The risk or severity of adverse effects can be increased when Tremelimumab is combined with Dostarlimab. Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Dostarlimab. Vedolizumab The risk or severity of adverse effects can be increased when Vedolizumab is combined with Dostarlimab. Pregnancy and Lactation US FDA pregnancy category Not Assigned Pregnancy Dostarlimab can cause harm to a fetus. The death of the fetus can occur from the immune system's reaction to the fetus through the examination of its mechanism in animal studies. Dostarlimab is a human immunoglobulin G (IgG4), which could permeate through the placental barrier. This may risk harm to the developing fetus as the drug may be passed on from the mother. Data is not available regarding the presence of dostarlimab in breast milk.[rx] Lactation Use should be avoided. Excreted into human milk: Unknown. Excreted into animal milk: Data not available Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during therapy and for at least 4 months after the last dose. How should this medicine be used?

Dostarlimab-gxly injection comes as a solution (liquid) to inject intravenously (into a vein) over 30 minutes by a doctor or nurse in a medical facility or infusion center. It is usually given once every 3 weeks for 4 cycles, and then once every 6 weeks for as long as your doctor recommends you receive treatment. Dostarlimab-gxly injection may cause serious or life-threatening reactions during an infusion. A doctor or nurse will watch you closely while you are receiving the infusion…

Continue exploring

Explore this topic across the RX Medical Library

Open a focused A–Z pathway or continue with closely related indexed articles. These links are educational and do not replace personal medical care.

Search this topic
Diseases A–Z Drugs A–Z Lab Tests A–Z Cancer A–Z
Diseases A–Z

Foodborne Illness (also foodborne disease and colloquially referred to as food poisoning)[rx] is any illness resulting from the spoilage of contaminated food, pathogenic bacteria, viruses, or parasites that…

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)